Canada - Tiếng Anh - Health Canada

pentapharm ltd. - triazolam - tablet - .25mg - triazolam .25mg - benzodiazepines

Nhật Bản - Tiếng Anh - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - triazolam - pale purple tablet, major axis: 7.9 mm, minor axis: 5.6 mm, thickness: 2.1 mm

Nhật Bản - Tiếng Anh - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - triazolam - white tablet, major axis: 7.0 mm, minor axis: 5.0 mm, thickness: 2.3 mm

Nhật Bản - Tiếng Anh - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - triazolam - faintly blue purple to light purple tablet, major axis: 7.9 mm, minor axis: 4.1 mm, thickness: 2.6 mm

Nhật Bản - Tiếng Anh - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - triazolam - blue to pale blue tablet with a split line, major axis: 7.9 mm, minor axis 4.1: mm, thickness 2.6: mm

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

generics (uk) limited - triazolam - tablets - 0.25 milligram

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - nefazodone hydrochloride (unii: 27x63j94gr) (nefazodone - unii:59h4fcv1tf) - tablet - 50 mg - nefazodone hydrochloride tablets, usp is indicated for the treatment of depression. when deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with nefazodone hydrochloride tablets, usp treatment (see warnings ). in many cases, this would lead to the conclusion that other drugs should be tried first. the efficacy of nefazodone in the treatment of depression was established in 6 to 8 week controlled trials of outpatients and in a 6-week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iiir category of major depressive disorder (see clinical pharmacology ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). it must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - lenacapavir sodium, quantity: 306.8 mg (equivalent: lenacapavir, qty 300 mg) - tablet, film coated - excipient ingredients: copovidone; poloxamer; mannitol; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sunlenca, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.